Cytokinetics Statistics Share Statistics Cytokinetics has 119.43M
shares outstanding. The number of shares has increased by 1.5%
in one year.
Shares Outstanding 119.43M Shares Change (YoY) 1.5% Shares Change (QoQ) 0.86% Owned by Institutions (%) 99.99% Shares Floating 117.02M Failed to Deliver (FTD) Shares 11,707 FTD / Avg. Volume 0.78%
Short Selling Information The latest short interest is 15.93M, so 13.34% of the outstanding
shares have been sold short.
Short Interest 15.93M Short % of Shares Out 13.34% Short % of Float 17.4% Short Ratio (days to cover) 10.85
Valuation Ratios The PE ratio is -8.94 and the forward
PE ratio is -6.48.
Cytokinetics's PEG ratio is
2.56.
PE Ratio -8.94 Forward PE -6.48 PS Ratio 285.13 Forward PS 24.2 PB Ratio -38.91 P/FCF Ratio -13.18 PEG Ratio 2.56
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Cytokinetics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 6.17,
with a Debt / Equity ratio of -5.83.
Current Ratio 6.17 Quick Ratio 6.17 Debt / Equity -5.83 Debt / EBITDA -1.6 Debt / FCF -1.97 Interest Coverage -6.2
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee $37.1K Profits Per Employee $-1.18M Employee Count 498 Asset Turnover 0.01 Inventory Turnover n/a
Taxes Income Tax n/a Effective Tax Rate 0%
Stock Price Statistics The stock price has increased by -40.9% in the
last 52 weeks. The beta is 0.65, so Cytokinetics's
price volatility has been higher than the market average.
Beta 0.65 52-Week Price Change -40.9% 50-Day Moving Average 34.81 200-Day Moving Average 42.46 Relative Strength Index (RSI) 39.54 Average Volume (20 Days) 1,502,319
Income Statement In the last 12 months, Cytokinetics had revenue of 18.47M
and earned -589.53M
in profits. Earnings per share was -5.26.
Revenue 18.47M Gross Profit 8.94M Operating Income -536.25M Net Income -589.53M EBITDA -493.48M EBIT -503.01M Earnings Per Share (EPS) -5.26
Full Income Statement Balance Sheet The company has 94.86M in cash and 788.68M in
debt, giving a net cash position of -693.82M.
Cash & Cash Equivalents 94.86M Total Debt 788.68M Net Cash -693.82M Retained Earnings -2.7B Total Assets 1.26B Working Capital 796.33M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -395.89M
and capital expenditures -3.91M, giving a free cash flow of -399.8M.
Operating Cash Flow -395.89M Capital Expenditures -3.91M Free Cash Flow -399.8M FCF Per Share -3.57
Full Cash Flow Statement Margins Gross margin is 48.41%, with operating and profit margins of -2902.72% and -3191.11%.
Gross Margin 48.41% Operating Margin -2902.72% Pretax Margin -3191.11% Profit Margin -3191.11% EBITDA Margin -2671.23% EBIT Margin -2902.72% FCF Margin -2164.1%
Dividends & Yields CYTK does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast The average price target for CYTK is $72,
which is 116.9% higher than the current price. The consensus rating is "Buy".
Price Target $72 Price Target Difference 116.9% Analyst Consensus Buy Analyst Count 15
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Jun 25, 2013. It was a
backward
split with a ratio of 1:6.
Last Split Date Jun 25, 2013 Split Type backward Split Ratio 1:6
Scores Altman Z-Score -2.12 Piotroski F-Score 2
